Cell and Gene Therapy Market, by Therapy Type (Cell Therapy and Gene Therapy), by Indication (Cardiovascular Disease, Cancer, Genetic Disorders, Infectious Diseases, Neurological Disorders, and Others), by Scale of Operation (In-house and Outsourced), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

  • Published On : Feb 2019 |
  • Pages : 164 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Cell and Gene Therapy Market – Rich Product Pipeline

Cell and gene therapy plays a major role in modern healthcare, as they provide concepts and techniques that can be used in gene regulation, cell-cell interactions, regenerative capacity, and remodeling.

The global cell and gene therapy market size was valued at US$ 6,020.0 million in 2017 and is expected to exhibit a CAGR of 21.9% over the forecast period (2018 – 2026).

Figure 1. Global Cell and Gene Therapy Market Value (US$ Mn), by Region, 2017

Cell & Gene Therapy  | Coherent Market Insights

                                                                     Source: Coherent Market Insights Analysis (2018)

Increasing prevalence of cardiovascular disease and cancer is expected to propel growth of cell and gene therapy market

Gene therapy aims at influencing the course of various genetic and acquired disorders at the genetic level whereas cell therapy targets various diseases at the cellular level i.e. by restoration of a certain cell population or using cells as carriers of therapeutic carrier. High prevalence of cardiovascular disease is expected to propel demand for cell and gene therapy, which in turn is expected to drive the market growth. According to the World Health Organization (WHO), May 2017, around 17.9 million people died due to cardiovascular disease in 2016 globally, which accounts for 31% of all worldwide deaths. According to WHO, in 2012, cancer was the second leading cause of morbidity and mortality globally, with around 14 million new cases registered in 2012 and in 2015, cancer was responsible for 8.8 million deaths, worldwide. Moreover, WHO stated that the number of new cases is expected to rise by around 70% by 2030.

Furthermore, introduction of effective guidelines is expected to propel growth of the global cell and gene therapy market over the forecast period. For instance, the U.S. Food and Drug Administration (FDA) included around 28 guidelines documents from 1998 to 2018 regarding various cell and gene therapies.

However, several development challenges such as safety and efficacy issues, lengthy procedures for conducting clinical studies, stringent regulatory framework, and high costs are expected to limit the adoption of cell and gene therapy, thereby hindering the market growth.

Figure 2. Global Cell and Gene Therapy Market Share (%), by Therapy Type,2018 and 2026

Cell & Gene Therapy  | Coherent Market Insights

                                                                     Source: Coherent Market Insights Analysis (2018)

Increasing prevalence of neurological disorders in North America is expected to bolster the market growth

North America holds dominant position in the global cell and gene therapy market, owing to high prevalence of genetic disorders. According to the U.S. Pharmacist Journal, January 2018, annually, around 1.2 million adults are diagnosed with early symptoms of brain disorders, of which 21% are due to Alzheimer’s disease, and the total number of new cases of Parkinson’s disease and traumatic brain injuries is around 135 million in U.S.

Moreover, increasing research and development activities is expected to increase demand for cell and gene therapy. According to the Catalyst report, in December 2018, around 289 novel cell and gene therapies were in development for a variety of diseases, of which around 111 medicines were for cancer and around 28 medicines were for cardiovascular disease. These medicines in development are either in clinical trials or awaiting for approval from the U.S. Food and Drug Administration (FDA).

Key Players

Major players operating in the global cell and gene therapy market include Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST.

 

Cell therapy is the administration of living cells in patients for the treatment of a disease. The source of cell can be autologous or allogeneic, which can be derived from stem cells such as bone marrow. Stem cells therapy is used in bone marrow transplantation. Gene therapy is the introduction, removal, or change in the patient's genetic code for treatment of a disease. Moreover, it modifies the expression of an individual’s genes or repair abnormal genes. The therapy involves administration of nucleic acid (DNA/RNA) with carriers called as vectors.

Market Dynamics

Increasing prevalence of cancer diseases is a major factor driving the cell and gene therapy market growth. According to the World Cancer Research Funds and the American Institute for Cancer Research, in 2018, there were around 18 million cases of cancer, of which around 9.5 million were in men and around 8.5 million in women, globally. Moreover, introduction of innovative products and rich pipeline of cell and gene therapy is expected to boost the market growth. For instance, around 150 gene therapies are currently in the development stage. Gene replacement accounts for around two third of gene therapy pipeline. However, around 49% of gene therapies are under preclinical and discovery stages. During 2012-18, around 351 gene therapy deals were signed. For instance Gilead’s Kite Pharma received exclusive rights to Sangamo Therapeutics’ zinc finger nuclease gene editing technology, for $3.2bn.  

Key features of the study:

  • This report provides in-depth analysis of the cell and gene therapy market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global cell and gene therapy market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the cell and gene therapy market

Detailed Segmentation:

  • Global Cell and Gene Therapy Market, By Therapy Type:
    • Cell Therapy
      • Stem Cells
      • T Cells
      • Dendritic Cells
      • NK Cells
      • Tumor Cells
    • Gene Therapy
  • Global Cell and Gene Therapy Market, By Indication:
    • Cardiovascular Disease
    • Cancer
    • Genetic Disorder
    • Infectious Disease
    • Neurological Disorders
    • Others
  • Global Cell and Gene Therapy Market, By Scale of Operation:
    • In House
    • Outsourced
  • Global Cell and Gene Therapy Market, By Geography:
    • North America
      • By Therapy Type:
        • Cell Therapy
          • Stem Cells
          • T Cells
          • Dendritic Cells
          • NK Cells
          • Tumor Cells
        • Gene Therapy
      • By Indication:
        • Cardiovascular Disease
        • Cancer
        • Genetic Disorder
        • Infectious Disease
        • Neurological Disorders
        • Others
      • By Scale of Operation:
        • In House
        • Outsourced
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Therapy Type:
        • Cell Therapy
          • Stem Cells
          • T Cells
          • Dendritic Cells
          • NK Cells
          • Tumor Cells
        • Gene Therapy
      •  By Indication:
        • Cardiovascular Disease
        • Cancer
        • Genetic Disorder
        • Infectious Disease
        • Neurological Disorders
        • Others
      • By Scale of Operation:
        • In House
        • Outsourced
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Therapy Type:
        • Cell Therapy
          • Stem Cells
          • T Cells
          • Dendritic Cells
          • NK Cells
          • Tumor Cells
        • Gene Therapy
      • By Indication:
        • Cardiovascular Disease
        • Cancer
        • Genetic Disorder
        • Infectious Disease
        • Neurological Disorders
        • Others
      • By Scale of Operation:
        • In House
        • Outsourced
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Therapy Type:
        • Cell Therapy
          • Stem Cells
          • T Cells
          • Dendritic Cells
          • NK Cells
          • Tumor Cells
        • Gene Therapy
      • By Indication:
        • Cardiovascular Disease
        • Cancer
        • Genetic Disorder
        • Infectious Disease
        • Neurological Disorders
        • Others
      • By Scale of Operation:
        • In House
        • Outsourced
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Therapy Type:
        • Cell Therapy
          • Stem Cells
          • T Cells
          • Dendritic Cells
          • NK Cells
          • Tumor Cells
        • Gene Therapy
      • By Indication:
        • Cardiovascular Disease
        • Cancer
        • Genetic Disorder
        • Infectious Disease
        • Neurological Disorders
        • Others
      • By Scale of Operation:
        • In House
        • Outsourced
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Therapy Type:
        • Cell Therapy
          • Stem Cells
          • T Cells
          • Dendritic Cells
          • NK Cells
          • Tumor Cells
        • Gene Therapy
      • By Indication:
        • Cardiovascular Disease
        • Cancer
        • Genetic Disorder
        • Infectious Disease
        • Neurological Disorders
        • Others
      • By Scale of Operation:
        • In House
        • Outsourced
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Amgen *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Biogen
    • BioMarin Pharmaceuticals
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline
    • Novartis
    • Pfizer
    • Regeneron Pharmaceuticals and Sanofi
    • Spark Therapeutics
    • Agilis Biotherapeutics
    • Angionetics AVROBIO
    • Freeline Therapeutics
    • Horama
    • MeiraGTx
    • Myonexus Therapeutics
    • Nightstar Therapeutics
    • Kolon TissueGene, Inc.
    • JCR Pharmaceuticals Co., Ltd.
    • MEDIPOST

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Therapy Type
      • Market Snippet, By Indication
      • Market Snippet, By Scale of Operation
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Diagnostic Algorithm
    • Pipeline Analysis
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
  4. Global Cell and Gene Therapy Market, By Therapy Type, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Cell Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
        • Stem Cells
        • T Cells
        • Dendritic Cells
        • NK Cells
        • Tumor Cells
    • Gene Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  5. Global Cell and Gene Therapy Market, By Indication, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Cardiovascular Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Genetic Disorder
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Infectious Disease
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Neurological Disorders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  6. Global Cell and Gene Therapy Market, By Scale of Operation, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • In-house
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Outsourced
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  7. Global Cell and Gene Therapy Market, By Region, 2018 – 2026, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Therapy Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Scale of Operation, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Therapy Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Scale of Operation, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Therapy Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Scale of Operation, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • Germany
        • U.K.
        • France        
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Therapy Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Scale of Operation, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Therapy Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Scale of Operation, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Therapy Type, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Scale of Operation, 2016 – 2026, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      •  Amgen
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Biogen
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • BioMarin Pharmaceuticals
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      •  Bristol-Myers Squibb Company
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline
        •  Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      •  Novartis
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Regeneron Pharmaceuticals and Sanofi
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Spark Therapeutics
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
      • Agilis Biotherapeutics
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      •  Angionetics AVROBIO
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Freeline Therapeutics
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Horama
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • MeiraGTx
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Myonexus Therapeutics
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Nightstar Therapeutics
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Kolon TissueGene, Inc.
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • JCR Pharmaceuticals Co., Ltd.
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      •  MEDIPOST
        • Company Overview
        • Therapy Type Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 28 figures on "Cell and Gene Therapy Market - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.